Drug Shortages Put Compounding Pharmacies in the Policy Spotlight

Persistent drug shortages are prompting lawmakers to reassess the role compounding facilities play in maintaining continuity of care.

America’s drug-supply chain has been running on thin margins for years. The cracks show up everywhere through antibiotics on backorder, hospital-administered medications rationed, and high-utilization generics that vanish from shelves without much warning. And millions of patients feel those gaps long before policymakers do.

This strain is especially visible in the ongoing shortage of GLP-1 medications such as tirzepatide. These therapies often get dismissed as lifestyle drugs, but they are nothing of the sort for the patients who rely on them to manage chronic conditions. For thousands managing obesity, insulin resistance, or Type 2 diabetes, consistent access is necessary to prevent clinical setbacks. So when a shortage hits, their entire disease-management plan is disrupted. Weight rebounds quickly, glycemic control deteriorates, cardiovascular risk rises, and more. For these patients, the consequences are clinical, not cosmetic.

When the United States supply chain cannot meet demand…